This content is from: Patents

Chugai wins licence dispute concerning US patent in UK High Court

The English High Court has ruled that Chugai no longer needs to pay royalties for its antibody product because it does not fall within the claims of UCB’s US patent

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | One Week Trial